Gu Meichen, Xu Tiankai, Chang Pengyu
Department of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, P.R. China.
Department of Radiation Oncology & Therapy, The First Hospital of Jilin University, No.71, Xinmin Str, Changchun, 130021, P.R. China.
Ther Adv Med Oncol. 2021 Apr 22;13:17588359211006950. doi: 10.1177/17588359211006950. eCollection 2021.
Lung adenocarcinomas exhibit various patterns of genomic alterations. During the development of this cancer, serves as a driver oncogene with a relatively high mutational frequency. Emerging data suggest that lung adenocarcinomas with mutations can show enhanced PD-L1 expression and additional somatic mutations, thus linking the prospect of applying immune checkpoint blockade therapy to this disease. However, the responses of -mutant lung adenocarcinomas to this therapy are distinct, which is largely attributed to the heterogeneity in the tumoral immune milieus. Recently, it was revealed that -mutant lung adenocarcinomas simultaneously expressing either a or mutation typically have different immune profiles of their tumours: tumours with a co-mutation generally present with a significant upregulation of PD-L1 expression and tumoricidal T-cell accumulation, and those with a co-mutation are frequently negative for PD-L1 expression and have few tumoricidal immune infiltrates. In this regard, interrogating or mutation in addition to PD-L1 expression will be promising in guiding clinical use of immune checkpoint blockade therapy for -mutant lung adenocarcinomas.
肺腺癌表现出多种基因组改变模式。在这种癌症的发展过程中， 作为一种驱动癌基因，具有相对较高的突变频率。新出现的数据表明，携带 突变的肺腺癌可表现出PD-L1表达增强和其他体细胞突变，从而将应用免疫检查点阻断疗法治疗该疾病的前景联系起来。然而，携带 突变的肺腺癌对这种疗法的反应各不相同，这在很大程度上归因于肿瘤免疫微环境的异质性。最近发现，同时表达 或 突变的携带 突变的肺腺癌通常具有不同的肿瘤免疫特征：携带 共突变的肿瘤通常表现为PD-L1表达显著上调和杀肿瘤性T细胞聚集，而携带 共突变的肿瘤PD-L1表达往往为阴性，且杀肿瘤性免疫浸润较少。在这方面，除了检测PD-L1表达外，检测 或 突变对于指导携带 突变的肺腺癌免疫检查点阻断疗法的临床应用具有前景。
